Page 1

idogen Idogen AB Interim report January 1- September 30 , 2021 FMS 28 / UP " The fact that we are now approaching the first clinical trial is therefore not only inspiring from the perspective that our technology will at last be evaluated in use with patients , but also entails a significantly stronger base for our business development . " Idogen AB ( publ ) Corp. Reg . no . 556756-8521 www.idogen.com Anders Karlsson , CEO